Matthew R. Henn, President and Chief Scientific Officer of Seres Therapeutics, Inc. (NASDAQ:MCRB), filed a Form 4 on November 17, 2026, disclosing restricted stock unit vestings and a tax-related sale of common stock on November 15 and 16, 2026.

Key Highlights

  • RSU vestings: Henn acquired 238 shares of common stock on November 15, 2026, through the settlement of restricted stock units under transaction code M.
  • Tax-related sale: 101 shares were sold on November 16, 2026, at $1.38 per share pursuant to a Rule 10b5-1 plan, solely to cover taxes on the vesting.
  • Resulting ownership: Following both transactions, Henn directly held 8,132 shares of common stock.
  • Derivative holdings: After the vesting, Henn retained 141 and 488 restricted stock units in two separate RSU tranches, both directly held.
  • 10b5-1 plan: According to the filing, the sale was effected pursuant to a Rule 10b5-1 instruction adopted by Henn on April 13, 2023.

RSU Vestings and Tax-Cover Sale by Seres Therapeutics President Henn

According to the filing, Matthew R. Henn, identified as President and Chief Scientific Officer, acquired 238 shares of Seres Therapeutics common stock on November 15, 2026, through the settlement of restricted stock units. The units carry no exercise price and each represents a contingent right to receive one share of issuer common stock, the filing stated.

Two separate RSU tranches contributed to the November 15 vesting: 141 units from a grant that began vesting at 25% on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, and 97 units from a grant that began vesting at 25% on February 15, 2025, under the same quarterly structure. The filing noted that neither tranche carries an expiration date.

On November 16, 2026, the filing reported a sale of 101 shares at $1.38 each. The filing stated that this sale "was effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units." After the sale, Henn's direct beneficial ownership in common stock stood at 8,132 shares, while remaining derivative holdings were reported as 141 and 488 restricted stock units across the two tranches.

What Was Disclosed

The Form 4 disclosed RSU vestings totaling 238 common shares and the subsequent sale of 101 shares at $1.38 for tax-coverage purposes under a pre-established Rule 10b5-1 plan, leaving Henn with 8,132 directly held common shares.